Clinical Research Directory
Browse clinical research sites, groups, and studies.
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
Sponsor: Peking Union Medical College Hospital
Summary
This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-Pentixafor PET imaging in patients with primary aldosteronism. And evaluates the potential of Al18F-NOTA-Pentixafor PET imaging in surgical strategy guidance.
Official title: Evaluation of Biodistribution, Dosimetry, Diagnostic and Surgery-guiding Ability of Al18F-NOTA-Pentixafor PET Imaging for Patients With Primary Aldosteronism: A Prospective, Single-center Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2023-12-30
Completion Date
2026-10-30
Last Updated
2025-02-26
Healthy Volunteers
No
Interventions
Al18F-NOTA-Pentixafor PET/CT
Participants will receive an intravenous injection of Al18F-NOTA-Pentixafor, prepared on-site and measured by qualified personnel using a dose calibrator, with readings and time recorded. The radiopharmaceutical will be slowly administered through a three-way stopcock, followed by a flush with 5 mL of normal saline. The recommended dose is approximately 4.81 MBq/kg (0.13 mCi/kg) body weight, with variations depending on drug yield and clinical scheduling. CT and PET imaging are planned 45-90 minutes after administration, with adjustments based on drug yield and equipment availability.
Locations (1)
Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, China